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Letter to the Editor 
Autosomal recessive congenital ichthyosis (ARCI) disrupts normal keratinization 
resulting in generalized scaling of the skin. There are presently no curative therapies available 
(Fleckman et al. 2013), local protein replacement is therefore an encouraging approach for a 
more specific treatment. ARCI refers to a heterogeneous group of rare skin keratinization 
disorders with an estimated prevalence of 1 in 50,000 – 200,000 (Dreyfus et al. 2014). The 
disease is characterized by notable impairments to the skin’s barrier-function, resulting in 
frequent infections and increased transepidermal water loss (TEWL). ARCI are caused by 
mutations in one of twelve identified genes involved in epidermal differentiation, the most 
common of which are loss of function mutations in TGM1 that affect ~30% of patients 
(Rodriguez-Pazos et al. 2009). TGM1 encodes transglutaminase 1 (TG1), a protein that plays 
an essential role in the formation of the cornified envelope (Eckert et al. 2005). Since animal 
models of severe keratinization disorders such as ARCI are not viable and animal skin is a poor 
representation of human skin (Gerber et al. 2014), the use of organotypic skin equivalents has 
emerged as a valid tool to investigate ARCI. In the present study, full thickness skin equivalents 
were generated from fibroblasts and keratinocytes of ARCI patients with mutations in TGM1 
and topically treated with TG1. Since biomacromolecules do not normally overcome the skin-
barrier owing to their high molecular weight, protein delivery was mediated by loading onto 
thermoresponsive nanogels (tNG) (Cuggino et al. 2011). tNGs have been shown to encapsulate 
proteins as large as 150 kDa, and to then release these upon thermal trigger (Giulbudagian et 
al. 2018b; Witting et al. 2015). Our groups previously reported the epidermal delivery of 
functional TG1 using tNGs to rescue the barrier defects of TGM1 knockdown skin equivalents 
(Witting et al. 2015). The transient nature of induced gene knockdowns, however, limits their 
usefulness. Additionally, it remains unclear whether TG1 loaded tNGs is an effective topical 
treatment for ARCI patients with TGM1 mutations.  
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To address this, full-thickness skin equivalents were generated from fibroblasts plus normal 
keratinocytes, keratinocytes with transient TGM1 knockdowns, or keratinocytes from ARCI 
patients with TGM1 mutations (Fig. 1). In comparison to normal equivalents, TGM1 
knockdown and Patient equivalents both demonstrated a slightly thinned SC and epidermis and 
a reduced cell number within the granular layer. The epidermal differentiation markers keratin 
14 and 10 were appropriately distributed. TG1 activity was present in normal skin equivalents 
but not in those generated from patient cells or TGM1 knockdown keratinocytes, in line with 
the inactivating mutations found in Patient 1 and the absence of persistent TG1 expression in 
Patient 2 and knockdown equivalents. Notably, decreasing efficiency of TGM1 repression in 
knockdown equivalents was observed with transcript levels recovery to >50% after 10 days 
cultivation (Fig S1).  
To assess the biocompatibility of TG1 loaded tNGs, normal keratinocytes and fibroblast 
monolayers and keratinocytes derived from Patients 1 and 2 were incubated with TG1 loaded 
tNGs for up to 48 h resulting in no significant cytotoxicity at any of the tested concentrations 
(Fig. 2, S2, S3). Concordantly, no significant cytotoxicity was observed following the 
application of tNGs onto skin equivalents (Fig. 2c). Additionally, the ability of TG1, either 
alone or loaded in tNGs, to enter keratinocytes was assessed by confocal microscopy. TG1 
entered the cytoplasm in a time-dependent manner, whereas tNGs were taken up more rapidly 
(Fig. S4). This and the lack of clear intracellular co-localization would suggest that the tNGs 
and TG1 enter keratinocytes separately, in line with the relatively quick release of protein at 
temperatures ≥ 35°C. Overall, however, tNGs coming into direct contact with cells of the viable 
epidermis is rather unlikely since there is evidence to show tNG are largely unable of 
overcoming the SC even of barrier deficient skin (Giulbudagian et al. 2018a).  
Finally, Patient 1 skin equivalents were treated topically with TG1 in solution or loaded 
in tNGs four times over eight days. Untreated Patient 1 equivalents demonstrated decreased 
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barrier function as shown by the significant increases in their apparent permeabilities (Papp) to 
testosterone as compared to normal equivalents (Fig. 2a). Following full treatment regimens 
with TG1-loaded tNGs, a significant decrease in Papp – indicating improved barrier function – 
was seen in a TG1 dose-dependent manner (Fig. 2a, d, S5). Activity staining confirmed the 
delivery of functional TG1 into viable epidermal layers (Fig. 2e) and the distribution of activity 
was comparable to normal equivalents. Improvement of barrier activity was confirmed by 
permeability tests with Lucifer Yellow (Fig. 2f) and N-hydroxy-sulfosuccinimide-LC-biotin 
(Fig. S6). The normalized amount of Lucifer Yellow fully passing the skin model was increased 
by more than 8-fold in patient models compared to control models, and reduced to 116% 
compared to controls following treatment with TG1-loaded tNGs, indicating a major 
restoration of the barrier function. Importantly, Papp was unaffected by the application of 
unloaded tNG or TG1 dissolved in PBS only (Fig. 2a, b). It is highly likely that the majority of 
TG1 penetrating into the viable epidermis did so independently of the tNGs since they do not 
overcome the stratum corneum (Giulbudagian et al. 2018a). 
The aim of this study was to further characterize the therapeutic potential of TG1 loaded 
tNGs in ARCI skin, as well as to better understand their mechanism of action based on a 
previously demonstrated proof-of-principle of epidermal delivery of TG1 by topical 
application of TG1 loaded tNGs (Witting et al. 2015).  Overall, these data verify that topical 
protein substitution could mitigate or even reverse the ARCI disease phenotype.  Notably, 
Traupe and colleagues previously demonstrated that topical applications of TG1 mixed with 
cationic liposomes successfully delivered the functional protein to skin equivalents made from 
TGM1 mutant ARCI patient cells, grafted onto humanized mice (Aufenvenne et al. 2013).  In 
contrast to our system, no changes to barrier function were observed upon treatment, likely a 
result of their model; grafted animals demonstrate compact hyperkeratosis unlike the typical 
skin-barrier ARCI phenotype, and showed transepidermal water loss close to normal levels.  
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In summary, topical TG1 replacement therapy is a highly promising therapeutic avenue for 
ARCI patients with disease-causing TGM1 mutations. The work here indicates TG1 delivery 
to the intercellular spaces between keratinocytes, and possibly their intracellular environments, 
can produce therapeutic improvements to the skin-barrier function of the ARCI phenotype. It 
is hypothesised that increasing the concentration or enzymatic activity of TG1 within the tNG 
will result in improved therapeutic efficacy and is the likely starting point for future 
development. The ability of tNGs to encapsulate a wide variety of proteins and deliver these 
past the SC of barrier deficient skin makes them a promising platform technology to treat a 
range of inflammatory and monogenic skin diseases.  
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Figure 1, Characterization of full-thickness skin equivalents: (a) cryosections of (i) 
normal, (ii) TGM1 knockdown, (iii) ARCI Patient 1 and (iv) ARCI Patient 2 skin equivalents. 
From left to right, images show H&E,  keratin 14 (green), keratin 10 (green), 
transglutaminase 1 (TG1; green), and TG1 activity staining (counter-staining with DAPI in 
blue). Scale bars = 50 µm. The dashed, yellow line indicates the epidermal – dermal junction. 
(b) The viability of normal human keratinocytes derived from healthy subject (black), Patient 
1 (light grey) or Patient 2 (dark grey) following (i) 24 h or (ii) 48 h incubation with TG1, 
tNGs and TG1 loaded tNGs as assessed by MTT assay. (iii) Viability of normal skin 
equivalents following full treatment regimen with TG1 loaded tNGs (5 µg/cm2 TG1, 500 
µg/cm2 tNG; applied 4 times over 8 days) as assessed by MTT assay; results are expressed as 
% untreated control. Statistical differences were assessed by one-way ANOVA with Dunnet’s 
correction for multiple comparisons (n = 3). Sodium dodecyl sulphate served as positive 
control, respectively. 
 
Figure 2, Skin-barrier function and transglutaminase 1 (TG1) activity of skin equivalents 
following TG1-loaded thermoresponsive nanogels (tNG) treatment: (a) Apparent 
permeabilities (Papp) of normal (white) or Patient 1 (gray shades) skin equivalents, untreated 
(UT) or following treatment with TG1 in phosphate buffered saline (PBS) or tNGs (n = 3, error 
bars = SEM, *p ≤ 0.05, **p ≤ 0.01). Corresponding permeation profiles of skin equivalents 
following treatment with (b) unloaded tNG, (c) TG1 in PBS or (d) TG1 loaded tNGs. The 
untreated controls (UT) are identical in all panels. (e) TG1 staining and activity in (i) Patient 1 
model treated with TG1/PBS (control), (ii) normal model treated with TG1/tNG, (iii) TG1 
knockdown model treated with TG1/tNG and (iv) Patient 1 model treated with TG1/tNG (blue 
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= DAPI, green = TG1 and biotinylated-cadaverine staining, respectively; scale bars = 50 µm). 
(f) Lucifer Yellow permeability in (i) normal skin model, (ii) Patient 1 skin model, and (iii) 
Patient 1 skin model treated with TG1/tNG. The dashed, yellow line indicates the epidermal-
dermal junction (blue = DAPI, green = Lucifer Yellow; scale bars = 75 µm).  


